Global Preclinical Cell and Gene Therapy Lead, and Head of Toxicology Subject Matter Experts, Safety Assessment/Toxicology, Labcorp
BIOGRAPHY
Speakers
-
Tracy Iles, BSc
Global Head of Method Development, Molecular Bioanalysis, LabcorpBIOGRAPHY -
Jay Herman, PhD
Toxicology Specialist, Study Director, LabcorpBIOGRAPHY -
Peter Sonnentag, MS
Study Director and Preclinical Ocular Toxicology Lead, LabcorpBIOGRAPHY -
Colin Guy, PhD
Senior Manager, GMP Research and Development, Biopharmaceutical CMC SolutionsBIOGRAPHY
Abstract
Watch the first of a three-part roundtable series that focus on approaches to accelerating your advanced therapy program by leveraging the combination of innovative technology and deep cross-industry insights from our cell and gene therapy scientists and operational leaders.
In this roundtable, the panel discuss novel innovations and strategies to accelerate timelines within preclinical development of your gene therapy. Specific areas of focus include:
In this roundtable, the panel discuss novel innovations and strategies to accelerate timelines within preclinical development of your gene therapy. Specific areas of focus include:
-
Optimizing analytical test development and validation for dose analysis, molecular bioanalysis, transgene bioanalysis and immunogenicity, etc.
-
Utilizing unique in vivo models requiring complex methods and routes of administration (e.g., intracranial, or ocular delivery, disease, or immunosuppressed models)
-
Driving cross-industry collaboration to support accelerating timelines and reducing risk
Watch roundtable 1: Key Considerations for Driving Gene Therapy Programs Successfully Through IND/CTA and Beyond
Watch roundtable 2: Accelerating Cell Therapy Clinical Trials With Comprehensive Biomarker-Driven Strategies
Watch roundtable 3: Companion Diagnostic Approaches in the Development of Cell and Gene Therapies
Watch roundtable 2: Accelerating Cell Therapy Clinical Trials With Comprehensive Biomarker-Driven Strategies
Watch roundtable 3: Companion Diagnostic Approaches in the Development of Cell and Gene Therapies
You May Also Like
MAR 26, 2024 | 7:00 PM
C.E. CREDITS
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
MAR 26, 2024 | 8:00 AM
C.E. CREDITS
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
MAR 26, 2024 | 11:00 AM
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
FEB 08, 2024 | 10:00 AM
High-content screening (HCS) is an imaging-based, multi-parametric strategy used in drug development that generates rich datasets through multiplexing strategically chosen fluorescent dyes a...
NOV 29, 2023 | 9:00 AM
Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and color...
DEC 05, 2023 | 8:00 AM
CGX10 Cell Isolation System: Introduction, Utility, and Assessment in a GMP-grade Environment for Multiparametric Cell Sorting A future of long-term, minimally toxic immunotherapy personaliz...
Loading Comments...
Finish Registering
-
APR 30, 2024Immuno-Oncology Virtual Event Series 2024
-
MAY 07, 20243rd International Biosecurity Virtual Symposium
-
MAY 23, 2024For the Love of Digital PCR 2024
- See More
-
APR 27, 2024
- See More
